
pmid: 37983119
The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
Sulbactam, Acinetobacter, Pneumonia, Bacterial, Humans, Drug Therapy, Combination, Microbial Sensitivity Tests, Azabicyclo Compounds, Acinetobacter Infections, Anti-Bacterial Agents
Sulbactam, Acinetobacter, Pneumonia, Bacterial, Humans, Drug Therapy, Combination, Microbial Sensitivity Tests, Azabicyclo Compounds, Acinetobacter Infections, Anti-Bacterial Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
